<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Management | Management | Infertility | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the initial management of infertility in primary care, including advice to couples, initial investigations, and when to refer. This scenario also provides brief information on what the couple might expect following a referral, and problems that may subsequently arise in primary care after assisted conception."/><meta data-react-helmet="true" property="og:description" content="Covers the initial management of infertility in primary care, including advice to couples, initial investigations, and when to refer. This scenario also provides brief information on what the couple might expect following a referral, and problems that may subsequently arise in primary care after assisted conception."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/infertility/management/management/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Management | Management | Infertility | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/infertility/management/management/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Infertility</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Management</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/infertility/","name":"Infertility"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/infertility/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Management"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Infertility: </span><span>Scenario: Management of infertility</span></h1><p class="page-header__lead"><span>Last revised in August 2018</span></p></div><p class="visually-hidden">Covers the initial management of infertility in primary care, including advice to couples, initial investigations, and when to refer. This scenario also provides brief information on what the couple might expect following a referral, and problems that may subsequently arise in primary care after assisted conception.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Infertility chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Initial assessment"><a aria-current="false" href="../initial-assessment/index.html"><span class="stacked-nav__content-wrapper">Scenario: Initial assessment</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Management"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Management</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#general-advice">General advice</a><ol aria-label="Sections within General advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-389">Basis for recommendation</a></li></ol></li><li><a href="index.html#when-to-start-initial-investigations">When to start initial investigations</a><ol aria-label="Sections within When to start initial investigations" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-527">Basis for recommendation</a></li></ol></li><li><a href="index.html#initial-investigations-in-a-woman">Initial investigations in a woman</a><ol aria-label="Sections within Initial investigations in a woman" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-67c">Basis for recommendation</a></li></ol></li><li><a href="index.html#initial-investigations-in-a-man">Initial investigations in a man</a><ol aria-label="Sections within Initial investigations in a man" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-708">Basis for recommendation</a></li></ol></li><li><a href="index.html#when-to-refer">When to refer</a><ol aria-label="Sections within When to refer" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#secondary-care-assessment-management">Secondary care (assessment and management):</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-15a">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-complications-of-assisted-conception">Managing complications of assisted conception</a><ol aria-label="Sections within Managing complications of assisted conception" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#complications-of-assisted-conception">Complications of assisted conception</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-f3a">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="management" class="ChapterBody-module--wrapper--2HCfk "><h2 id="management" class="visually-hidden">Scenario: Management of infertility</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4a5ea442-a9be-4b41-82d6-2ae394d6df4c --><!-- begin field c343173e-93f5-4449-b33e-acbc0159151a --><p>From age 18 years onwards.</p><!-- end field c343173e-93f5-4449-b33e-acbc0159151a --><!-- end item 4a5ea442-a9be-4b41-82d6-2ae394d6df4c --></div><section aria-labelledby="general-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="general-advice">How should I advise a couple seeking information on infertility?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 017ee26a-4513-4000-90fb-11b4c60ad476 --><!-- begin field c5ceff50-7a40-4139-839c-875028e1b376 --><ul><li><strong>Involve both partners in all aspects of management.</strong> It is important to discuss their wishes and plans.</li><li><strong>Offer information about normal patterns of conception.</strong><ul><li>Advise that about 84% of couples in the general population (which covers all ages and includes people with fertility problems) will conceive naturally within 1 year if they have regular (every 2–3 days) unprotected sexual intercourse. This rises cumulatively to 92% after 2 years and 93% after 3 years.</li><li>For many couples, this information will provide reassurance that they have a good chance of conception and may be all that they need.</li><li>In general, do not advise investigations for infertility until the couple has been unable to conceive after 1 year of regular unprotected sexual intercourse.</li></ul></li><li><strong>Advise regular (every 2–3 days) sexual intercourse throughout the woman's cycle. </strong>This should ensure that intercourse falls within the fertile period.<ul><li>Do not recommend the use of temperature charts or luteinizing hormone detection methods.</li></ul></li><li><strong>Also offer advice on the following (as appropriate):</strong><ul><li><strong>General health issues</strong><ul><li>Advise women on preparation for pregnancy (such as taking folic acid).</li><li>Check rubella status.</li><li>Offer cervical screening in accordance with the national cervical screening programme.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../../pre-conception-advice-and-management.html">Pre-conception - advice and management</a> for more information.</li></ul></li><li><strong>Stress management</strong><ul><li>Inform couples that stress in either partner can affect their relationship and is likely to reduce libido and frequency of intercourse, which can contribute to fertility problems.</li><li>Explain that fertility problems, as well as the investigation and treatment of fertility problems, can cause psychological stress. Offer counselling before, during, and after investigation and treatment irrespective of the outcome.</li></ul></li><li><strong>Smoking</strong><ul><li>Advise women who smoke that smoking is likely to reduce their fertility and that passive smoking is likely to reduce their chances of conceiving.</li><li>Advise men that smoking is associated with reduced semen quality and that stopping smoking will improve their general health.</li><li>Offer referral to a smoking cessation programme. See the CKS topic on <a class="topic-reference external-reference" href="../../../smoking-cessation/index.html">Smoking cessation</a> for more information.</li></ul></li><li><strong>Weight</strong><ul><li>Advise women to aim for a body mass index (BMI) of 19–25 kg/m<sup>2</sup>.</li><li>In particular, encourage weight loss in women with a BMI greater than 29 kg/m<sup>2</sup>, as weight loss is likely to increase their chance of ovulation and therefore conception.</li><li>Advise women with a BMI less than 19 kg/m<sup>2 </sup>plus either amenorrhoea or irregular menstruation that gaining weight is likely to increase their chance of conception.</li><li>Inform women that participating in a group programme involving exercise and dietary advice increases the chances of pregnancy.</li><li>Advise men with a BMI greater than 29 kg/m<sup>2 </sup>that they are likely to have reduced fertility and that they should lose weight.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li></ul></li><li><strong>Occupational risks</strong><ul><li>Advise anyone concerned about occupational risks to their health, including their fertility, to seek specialist advice from occupational health at their place of work or from the <a data-hyperlink-id="a1ca8107-96f4-4ee4-8ff2-a98900e795ea" href="http://www.hse.gov.uk/">Health and Safety Executive</a> website, which provides detailed information on occupational risks. </li></ul></li><li><strong>Alcohol</strong><ul><li>Inform women that although the evidence on the effect of alcohol on fertility is inconsistent, alcohol poses a definite risk to the fetus, and the Department of Health now recommends consumption of no alcohol at all whilst trying to conceive. </li><li>Inform men that excessive alcohol consumption can be detrimental to semen quality, but alcohol consumption within the Department of Health's recommendations of no more than 14 units of alcohol a week is unlikely to affect their fertility.</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../alcohol-problem-drinking/index.html">Alcohol - problem drinking</a> for more information.</li></ul></li><li><strong>Drugs</strong><ul><li>Inform women and men that some prescription and over-the-counter <a class="topic-reference internal-reference" href="../../background-information/causes-of-infertility/index.html">drugs</a> can interfere with fertility.</li><li>Advise that the use of illicit drugs may affect fertility. Offer users of illicit drugs referral to a specialist drugs and alcohol service.</li><li>Advise people trying to conceive that the effectiveness of complementary therapies has not been properly evaluated, and these therapies are not recommended.</li></ul></li><li><strong>Other possible risk factors</strong><ul><li>Inform women and men that there is no consistent evidence of an association between consumption of caffeinated beverages and fertility problems.</li><li>Inform men that although an elevated scrotal temperature is associated with reduced semen quality, it is uncertain whether wearing loose-fitting underwear improves semen quality.</li></ul></li></ul></li><li><strong>Provide sources of additional information and support. </strong>For example:<ul><li>British Infertility Counselling Association (<a data-hyperlink-id="3076fe22-63ee-46b8-9cae-a98900e79606" href="http://www.bica.net/">www.bica.net</a>) is a professional association for infertility counsellors and counselling in the UK.</li><li>Fertility Network UK (<a data-hyperlink-id="9ac5abde-7c30-41cc-8057-a98900e7968a" href="http://fertilitynetworkuk.org/">fertilitynetworkuk.org</a>) is a national charity for people with fertility problems.</li><li>The Human Fertilisation and Embryology Authority (<a data-hyperlink-id="20e19239-8787-48ee-8d05-a98900e796b1" href="http://www.hfea.gov.uk/">www.hfea.gov.uk</a>) oversees the use of gametes and embryos in fertility treatment and research, and provides impartial information to all affected by fertility treatment. Information provided by the HFEA to <a data-hyperlink-id="1ccb64f6-0a76-42b6-a16e-a98900e796e5" href="http://www.hfea.gov.uk/en/294.html">patients, donors, and healthcare professionals</a> includes:<ul><li>Detailed information on all <a data-hyperlink-id="5de9d99f-56a8-48a7-b8ef-a98900e79708" href="http://guide.hfea.gov.uk/guide/">UK fertility clinics</a>, including the services they provide and their success rates.</li><li>Information on potential treatments and their success rate.</li></ul></li><li>NHS A-Z (<a data-hyperlink-id="24e04aa8-1171-4e01-b590-a98900e7971e" href="https://www.nhs.uk/conditions/">www.nhs.uk</a>) has information on <a data-hyperlink-id="dcc03159-4d0a-4806-9b06-a98900e79741" href="https://www.nhs.uk/conditions/infertility/treatment/">Fertility and conception</a>.</li><li>The National Institute for Health and Care Excellence (NICE, <a data-hyperlink-id="9a1bdf81-3809-4d8c-a3e8-a98900e797c3" href="https://www.nice.org.uk/">www.nice.org.uk</a>) has published <a data-hyperlink-id="5fde64c6-69d1-4216-b3e7-a98900e797da" href="http://ttps//www.nice.org.uk/guidance/cg156/ifp/chapter/About-this-information">Information for the public</a> on the assessment and treatment of fertility problems.</li><li>The British Fertility Society (<a data-hyperlink-id="7e2449c7-4374-4d42-bc47-a98900e79a81" href="https://britishfertilitysociety.org.uk/">britishfertilitysociety.org.uk</a>), with associated Specialist Societies, has produced a series of <a data-hyperlink-id="0feff147-797d-4e45-8d34-a98900e79d1e" href="https://britishfertilitysociety.org.uk/public-resources/">Quick Guides</a> to specialist areas of fertility assessment and treatment. </li></ul></li></ul><!-- end field c5ceff50-7a40-4139-839c-875028e1b376 --><!-- end item 017ee26a-4513-4000-90fb-11b4c60ad476 --></div><section aria-labelledby="basis-for-recommendation-389" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-389">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 389578ce-b15e-44f5-afc1-7f8a6f760ed1 --><!-- begin field baf1696c-dc88-44d1-a8c4-f329e8d45a34 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Fertility: assessment and treatment for people with fertility problems</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</p><h5>Involving both partners in the consultation</h5><ul><li>Two surveys identified by NICE reported that women are more satisfied if seen with their partners at their infertility consultation [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><h5>Information on the normal pattern of conception</h5><ul><li>This information is based on the NICE guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>] and the Human Fertilisation and Embryology Authority (HFEA) <em>Fertility treatment 2014: Trends and figures </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">HFEA, 2016</a>].</li><li>Expert opinion in a Committee Statement developed by the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Reproductive Medicine (ASRM) is that education and enhanced awareness of the effect of age on fertility are essential in counselling couples who are concerned about infertility [<a class="bibliography-reference internal-reference" href="../../references/index.html">ACOG/ASRM, 2014</a>].</li></ul><h5>Advising regular sexual intercourse and not recommending the use of temperature charts or luteinizing hormone (LH) detection methods</h5><ul><li>Evidence from well-designed non-experimental descriptive studies identified by NICE suggests that sexual intercourse every 2–3 days is likely to maximize the overall chance of natural conception, as spermatozoa survive in the female reproductive tract for up to 7 days after insemination [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li>Evidence from six cohort studies that evaluated the use of basal body temperature or urinary LH kits to time intercourse showed that use of these kits causes stress. Moreover, they have not been shown to improve conception rates. The use of these kits is therefore not routinely recommended. However, NICE states that use of LH kits to predict ovulation can be useful for a minority of couples who find it difficult to have frequent sexual intercourse [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><h5>Smoking</h5><ul><li>NICE advises that smoking is likely to impair fertility [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li>Evidence from a systematic review and a meta-analysis of observational studies shows that smoking and reduced fertility in women are significantly associated [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hughes and Brennan, 1996</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Augood et al, 1998</a>].</li><li>Evidence from a longitudinal study shows that passive smoking is detrimental to fertility in women [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hull et al, 2000</a>]. In men, there is no clear evidence that smoking delays conception or affects fertility, but it may affect sperm quality and general health [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul></li></ul><h5>Weight</h5><ul><li>Obesity can impair fertility in both women and men. It can also lead to complications during pregnancy as well as adverse effects on the offspring [<a class="bibliography-reference internal-reference" href="../../references/index.html">ASRM, 2015</a>].</li><li>Evidence identified by NICE shows that women with a body mass index (BMI) greater than 30 kg/m<sup>2 </sup>take longer to conceive than women with a lower BMI, even after adjustment for other factors, such as menstrual irregularity [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li>For infertile anovulatory women with a BMI greater than 29 kg/m<sup>2</sup>, there is evidence that a supervised weight loss programme or a group programme including exercise, dietary advice, and support helps to reduce weight, resume ovulation, and improve pregnancy rates [<a class="bibliography-reference internal-reference" href="../../references/index.html">Clark et al, 1998</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul></li><li>There is no proven association between male obesity and infertility, although observational studies have found that obesity is associated with poorer general health, a reduction in sperm motility, and increased sperm DNA fragmentation [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kort et al, 2003a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Kort et al, 2003b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li>An observational study reported an inverse relationship between BMI and the total number of normal motile sperm. Men who were overweight (BMI 25–30 kg/m<sup>2</sup>) had a significantly reduced number of motile sperm compared with men with normal body weight (BMI 20–24 kg/m<sup>2</sup>) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kort et al, 2003b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul></li></ul><h5>Occupational risks</h5><ul><li>Some occupations involve exposure to hazards that can reduce male or female infertility. Evidence suggestive of a harmful effect on the human reproductive system has been recognised for specific agents, such as heat, metals, pesticides, and X-rays, but information on the association of most chemical and physical agents with infertility is lacking, mainly because these agents were rapidly introduced into industry [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li>More than 104,000 chemical and physical agents have been identified in the workplace, but at least 95% of these have not been assessed for their effect on reproduction [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><h5>Alcohol</h5><ul><li>The recommendation on alcohol use by women is based on advice from the Department of Health (DOH), who now recommend no alcohol consumption when trying to conceive [<a class="bibliography-reference internal-reference" href="../../references/index.html">DH, 2012</a>].</li><li>NICE states that [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>]:<ul><li>The evidence for a link between alcohol and female infertility is inconsistent, but excessive alcohol consumption is harmful to the fetus.</li><li>Excessive alcohol consumption can be detrimental to semen quality, but the effect is reversible and there is no evidence for a causal relationship between moderate alcohol consumption and poor semen quality.</li></ul></li></ul><h5>Other risk factors</h5><ul><li><strong>Caffeine</strong> — the association between caffeine and female infertility is inconsistent. NICE found no studies on the effect of caffeine on pregnancy rates or the effect of decaffeinated beverages on fertility. One observational study of caffeine intake and male fertility found no evidence of an association between caffeine intake and poor semen variables. However, the combination of coffee drinking with smoking diminished sperm motility and increased the proportion of dead sperm [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li><strong>Complementary therapies</strong> — the recommendation on complementary therapies is based on the expert opinion of the NICE GDG, who advise that the effectiveness of complementary therapies for fertility problems has not been probably evaluated and that further research is needed before such interventions can be recommended [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li><strong>Recreational drugs</strong> — marijuana and cocaine can adversely affect ovulatory and tubal function, and anabolic steroids and cocaine can adversely affect semen quality.  NICE found no studies that assessed the effect of recreational drug use on pregnancy rates [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li><strong>Heat exposure</strong> — well-designed non-experimental descriptive studies identified by NICE have shown that increased scrotal temperature is closely associated with reduced semen quality in healthy men and that a sedentary work position and occupational heat exposure are associated with abnormal semen quality [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li><strong>Tight-fitting underwear</strong> — evidence on the effect of tight-fitting compared with loose-fitting underwear on semen quality is limited and conflicting:<ul><li>Evidence from a cohort study of 97 men with subfertility showed that scrotal temperatures and semen variables did not differ between a group wearing boxer shorts and a group wearing briefs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Munkelwitz and Gilbert, 1998</a>].</li><li>Evidence from a very small (n = 20) prospective randomized crossover trial which only 9 men completed suggested that wearing tight-fitting underwear can impair semen quality, whereas wearing loose-fitting underwear had no effect on semen quality [<a class="bibliography-reference internal-reference" href="../../references/index.html">Tiemessen et al, 1996</a>]. The effect of impaired semen quality on pregnancy rates has not been established [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul></li></ul><!-- end field baf1696c-dc88-44d1-a8c4-f329e8d45a34 --><!-- end item 389578ce-b15e-44f5-afc1-7f8a6f760ed1 --></div></section></section><section aria-labelledby="when-to-start-initial-investigations" class="ChapterBody-module--wrapper--2HCfk "><h3 id="when-to-start-initial-investigations">When should I start initial investigations in a couple concerned about infertility?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9ff33f3f-e117-4a6d-ad33-f10d069c7b22 --><!-- begin field a6e5c36c-5aea-46b3-bd3f-1d3ca891176e --><ul><li>Start investigations in couples who have not conceived after 1 year of regular (every 2–3 days) unprotected sexual intercourse.</li><li>Offer investigations earlier than 1 year to couples who have been identified as less likely to conceive. Early investigations may be prompted by the same factors that prompt an <a class="topic-reference internal-reference" href="index.html#when-to-refer">early referral</a>.</li></ul><!-- end field a6e5c36c-5aea-46b3-bd3f-1d3ca891176e --><!-- end item 9ff33f3f-e117-4a6d-ad33-f10d069c7b22 --></div><section aria-labelledby="basis-for-recommendation-527" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-527">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 527d96cd-4d58-4690-9f81-d7f75ba65f33 --><!-- begin field 1b7915ee-4e2a-40ec-b7e6-8ff873298aa9 --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Fertility: assessment and treatment for people with fertility problems</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</p><!-- end field 1b7915ee-4e2a-40ec-b7e6-8ff873298aa9 --><!-- end item 527d96cd-4d58-4690-9f81-d7f75ba65f33 --></div></section></section><section aria-labelledby="initial-investigations-in-a-woman" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-investigations-in-a-woman">What initial investigations should I arrange in a woman?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ba7e1fce-61c1-4ae6-9aa8-e125a35412f0 --><!-- begin field 47a0e68c-88ff-4264-9c87-f11f309e81d0 --><ul><li><strong>Measure mid-luteal phase progesterone in all women to confirm ovulation. </strong>The sample should be taken 7 days before the expected period (for example day 21 of a 28-day cycle).</li><li><strong>Screen for chlamydia.</strong> <ul><li>See the section on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/diagnosis/testing-to-confirm-the-diagnosis/index.html">Testing to confirm the diagnosis</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/index.html">Chlamydia - uncomplicated genital</a> for more information.</li></ul></li><li><strong>The following additional tests may be needed:</strong><ul><li>Serum progesterone (in women with prolonged irregular menstrual cycles) — depending on the timing of menstrual periods, serum progesterone may need to be measured later (for example on day 28 of a 35-day cycle) to confirm ovulation, and repeated weekly thereafter until the next menstrual cycle starts.</li><li>Gonadotrophin measurement (in women with irregular menstrual cycles) — gonadotrophin (follicle-stimulating hormone and luteinizing hormone) measurements are of value in women with anovulation or oligo-ovulation and can be used to identify <a class="topic-reference internal-reference" href="../../background-information/causes-of-infertility/index.html#causes-of-infertility-in-women">ovulation disorders</a>.</li><li>Thyroid function tests (in women with symptoms of thyroid disease).</li><li>Prolactin measurement (in women with symptoms of an ovulatory disorder [for example polycystic ovary syndrome], galactorrhoea, or a suspected pituitary tumour).</li></ul></li><li><strong>The following investigations are <em>not </em>recommended:</strong><ul><li>Basal body temperature charts.</li><li>Use of ovulation predictor kits.</li><li>Postcoital testing.</li></ul></li></ul><!-- end field 47a0e68c-88ff-4264-9c87-f11f309e81d0 --><!-- end item ba7e1fce-61c1-4ae6-9aa8-e125a35412f0 --></div><section aria-labelledby="basis-for-recommendation-67c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-67c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 67c76033-785a-421b-8b05-0506d9c52dd0 --><!-- begin field a136e0ec-2fb1-4f75-b714-a875c619517f --><p>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Fertility: assessment and treatment for people with fertility problems</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</p><h5>Mid-luteal phase progesterone levels</h5><ul><li>Progesterone is released after luteinization of the follicle (as part of the ovulation process). Ovulation can be confirmed retrospectively by measurement of serum progesterone in the mid-luteal phase, approximately on day 21 of a 28-day cycle [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><h5>Gonadotrophin measurement</h5><ul><li>Gonadotrophin measurement is of value in women with anovulation or oligo-ovulation and can be used to identify the <a class="topic-reference internal-reference" href="../../background-information/causes-of-infertility/index.html#causes-of-infertility-in-women">three groups of ovulation disorders</a> (as defined by the World Health Organization) [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><h5>Thyroid function tests</h5><ul><li>Thyroid dysfunction can lead to menstrual and ovulatory disorders associated with infertility [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>]:<ul><li>Abnormal thyroid function has been reported in 1.3–5.1% of infertile women.</li><li>Subclinical hypothyroidism has been estimated to occur in 0.88–11.3% of women with ovulation disorders.</li></ul></li><li>Expert opinion in the NICE guideline is that women with possible fertility problems are no more likely than the general population to have thyroid disease. Therefore, thyroid function tests should only be done in women with symptoms of thyroid disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><h5>Prolactin measurement</h5><ul><li>Hyperprolactinaemia is an endocrine disorder caused by increased prolactin secretion from the pituitary gland. This can result in galactorrhoea, irregular menstruation, and infertility [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li>Evidence identified by NICE shows that the incidence of an increased prolactin level in infertile but ovulatory women ranges from 3.8–11.5%.</li><li>NICE recommends that prolactin measurement should be reserved for women with symptoms of an ovulatory disorder (for example polycystic ovary syndrome), galactorrhoea, or a pituitary tumour.</li></ul><h5>Screening for chlamydia</h5><ul><li>The NICE GDG points out that although the prevalence of <em>Chlamydia trachomatis</em> among subfertile women in the UK is only 1.9%, uterine instrumentation carried out routinely as part of the infertility investigation may reactivate or introduce upper tract dissemination of endocervical chlamydial infection, resulting in iatrogenic pelvic inflammatory disease (PID). For this reason, the NICE GDG recommends that all women scheduled to undergo uterine instrumentation be tested for chlamydia [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>]. CKS therefore recommends that chlamydia screening be part of the assessment of all women presenting with infertility.</li></ul><h5>Tests not recommended</h5><ul><li>Basal body temperature charts are not recommended because they do not reliably predict ovulation [<a class="bibliography-reference internal-reference" href="../../references/index.html">Guermandi et al, 2001</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li>Ovulation predictor kits are widely available, but there is no evidence that attempts to time sexual intercourse to the menstrual cycle result in improved conception rates. Furthermore, there is evidence that use of these kits causes stress [<a class="bibliography-reference internal-reference" href="../../references/index.html">Hargreave and Mills, 1998</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Chambers, 1999</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li>NICE states that use of luteinizing hormone kits to predict ovulation can be useful for a minority of couples who find it difficult to have frequent sexual intercourse [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul></li><li>The routine use of postcoital testing is not recommended as it has no predictive value for pregnancy rates [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><!-- end field a136e0ec-2fb1-4f75-b714-a875c619517f --><!-- end item 67c76033-785a-421b-8b05-0506d9c52dd0 --></div></section></section><section aria-labelledby="initial-investigations-in-a-man" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initial-investigations-in-a-man">What initial investigations should I arrange in a man?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4d4c1dbb-393b-4b88-aea1-449a75c542cf --><!-- begin field 6f8c6b38-2cf3-4eb8-9f78-18be0c2b19a5 --><ul><li><strong>Arrange for semen analysis. </strong><ul><li>Give clear written and verbal instructions concerning the collection of the semen sample, including that:<ul><li>The semen sample should be collected after at least 2 days but no more than 7 days of sexual abstinence.</li><li>Ideally, the sample should be collected in a private room near the laboratory. If this is not possible, the sample should be delivered to the laboratory within 1 hour of production.</li><li>The specimen should be collected by masturbation; ejaculated into a clean, wide-mouthed glass or plastic container; and protected from extremes of temperature (below 20°C or above 37°C).</li></ul></li><li>Emphasize that the semen sample needs to be complete and that the man should report any loss of any fraction of the sample.</li><li>Interpret the result using the most recent <a href="http://apps.who.int/iris/bitstream/handle/10665/44261/9789241547789_eng.pdf;jsessionid=E8F26821D5EEEBE98FE9A59777B34225?sequence=1" data-hyperlink-id="5f39bc72-91c7-4d61-89d2-a98900e78fe9">World Health Organization laboratory manual for the examination and processing of human semen</a>.<ul><li>If the result of the first semen sample is normal, there is no need to do a repeat confirmatory test.</li><li>If the result of the first semen sample is abnormal, order a repeat test.<ul><li>Testing should ideally be repeated 3 months after the initial test, to allow time for the cycle of spermatozoa to be completed.</li><li>It may be appropriate to test earlier (for example if the man is very anxious regarding the test result and prefers to have the test done earlier). In these circumstances, or if there is a gross spermatozoa deficiency (azoospermia or severe oligospermia), perform the repeat test within 2–4 weeks.</li></ul></li><li>If the repeat test result is normal, regard the semen as normal; no further testing is required.</li><li>Refer men who have two abnormal semen examination results to secondary care for further assessment.</li></ul></li></ul></li><li><strong>Screen for chlamydia.</strong> <ul><li>See the section on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/diagnosis/testing-to-confirm-the-diagnosis/index.html">Testing to confirm the diagnosis</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/index.html">Chlamydia - uncomplicated genital</a> for more information.</li></ul></li><li><strong>The following tests are <em>not</em> recommended:</strong><ul><li>Postcoital testing.</li><li>Screening for antisperm antibodies.</li></ul></li></ul><!-- end field 6f8c6b38-2cf3-4eb8-9f78-18be0c2b19a5 --><!-- end item 4d4c1dbb-393b-4b88-aea1-449a75c542cf --></div><section aria-labelledby="basis-for-recommendation-708" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-708">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 70826a2f-9f60-4e0d-9da1-70a74f3661d4 --><!-- begin field 14f111c6-20f3-4f19-82f8-f116f9d26ef7 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Fertility: assessment and treatment for people with fertility problems</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>]. The recommendations on how sperm sample should be collected is based on the World Health Organization (WHO) <em>Laboratory Manual for the Examination of Human Semen and Sperm–Cervical Mucus Interaction</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">WHO, 2010</a>].</p><h5>Semen analysis and chlamydia testing </h5><ul><li>Due to the range of causes of infertility, NICE recommends appropriate investigations in men, including semen analysis and screening for infections, such as <em>Chlamydia trachomatis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li><em>C. trachomatis </em>is<em> </em>a major cause of pelvic inflammatory disease, leading to chronic abdominal pain, ectopic pregnancy, and tubal factor infertility [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul></li></ul><h5>Emphasizing that the semen sample for analysis is complete </h5><ul><li>The WHO advises that it is important to emphasize that the semen sample needs to be complete. This is because during ejaculation, the first semen fractions voided are mainly sperm-rich prostatic fluids, whereas later fractions are dominated by seminal vesicular fluid. [<a class="bibliography-reference internal-reference" href="../../references/index.html">WHO, 2010</a>].</li></ul><h5>Interpreting the result of the semen analysis</h5><ul><li>The recommendation to interpret the result of the semen analysis using the most recent <a href="http://apps.who.int/iris/bitstream/handle/10665/44261/9789241547789_eng.pdf;jsessionid=E8F26821D5EEEBE98FE9A59777B34225?sequence=1" data-hyperlink-id="efc596ff-f132-493c-b8d9-a989010059e3">World Health Organization laboratory manual for the examination and processing of human semen</a> is based on the NICE guideline. NICE highlights that the WHO criteria are described as 'reference' values rather than 'normal' values and are based on populations of fertile men [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li>The NICE guideline development group (GDG) reviewed the evidence in relation to the detection of male factor fertility problems and found that basic semen analysis using the WHO criteria is sensitive (sensitivity of 89.6% — that is the test is likely to detect 9 of 10 men who have 'true' semen abnormality) but has poor specificity (that is, an abnormal test result does not always mean there is a true semen abnormality) [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li>Based on this, the NICE GDG concluded that greater specificity can be achieved with repeated testing — a single-sample analysis will falsely identify about 10% of men as abnormal, but repeating the test reduces this to 2%. To reduce false-positive results, a repeat semen analysis should be performed if the results of the first analysis is abnormal [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul></li></ul><h5>Tests not recommended</h5><ul><li>The routine use of postcoital testing is not recommended as it has no predictive value for pregnancy rates [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li>Screening for antisperm antibodies is not recommended as the significance of antisperm antibodies is unclear and there is no evidence of effective treatment to improve fertility [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><!-- end field 14f111c6-20f3-4f19-82f8-f116f9d26ef7 --><!-- end item 70826a2f-9f60-4e0d-9da1-70a74f3661d4 --></div></section></section><section aria-labelledby="when-to-refer" class="ChapterBody-module--wrapper--2HCfk "><h3 id="when-to-refer">When should I refer a couple presenting with infertility?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9a107e46-6451-480e-96f3-547858a4c548 --><!-- begin field 5531b815-26da-48f9-8373-eba2ccc187fa --><p><strong>Referral criteria for people presenting with infertility may vary between health authorities. </strong><strong>Refer to local guidelines.</strong></p><ul><li><strong>For woman younger than 36 years of age:</strong><ul><li>In general, consider referral (for further <a class="topic-reference internal-reference" href="index.html#secondary-care-assessment-management">assessment and management</a>), along with her partner, if history, examination, and investigations are normal in both partners and the couple has not conceived after 1 year.</li></ul></li><li><strong>Consider earlier referral</strong><strong> if the following factors are present:</strong><ul><li><strong>In women:</strong><ul><li>Age 36 years and older (refer after 6 months).</li><li>Amenorrhoea or oligomenorrhoea.</li><li>Previous abdominal or pelvic surgery.</li><li>Previous pelvic inflammatory disease.</li><li>Previous sexually transmitted infection (STI).</li><li>Abnormal pelvic examination.</li><li>Known reason for infertility (for example prior treatment for cancer).</li></ul></li><li><strong>In men:</strong><ul><li>Previous genital pathology.</li><li>Previous urogenital surgery.</li><li>Previous STI.</li><li>Varicocele.</li><li>Significant systemic illness.</li><li>Abnormal genital examination.</li><li>Known reason for infertility (for example prior treatment for cancer).</li></ul></li></ul></li><li><strong>Ensure that the couple has been offered counselling</strong> before, during, and after investigation and treatment, regardless of the outcome of these procedures. Explain that fertility problems and their investigation and treatment can cause psychological stress.<ul><li>Usually counselling will be arranged by the specialist infertility team.</li><li>Infertility counsellors are provided by all licensed clinics in the UK, and the British Infertility Counselling Association (<a href="http://www.bica.net/" data-hyperlink-id="466e9892-9c3c-422c-a161-a989010042dc">www.bica.net</a>).</li></ul></li></ul><!-- end field 5531b815-26da-48f9-8373-eba2ccc187fa --><!-- end item 9a107e46-6451-480e-96f3-547858a4c548 --></div><section aria-labelledby="secondary-care-assessment-management" class="ChapterBody-module--wrapper--2HCfk "><h4 id="secondary-care-assessment-management">Secondary and tertiary care (assessment and management)</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 20205266-75f4-4891-94f8-a8bb00b6f82a --><!-- begin field 4d46f176-5a8e-4c4d-9c50-a8bb00b6fa40 --><ul><li><strong>Investigations in women </strong>normally include tubal patency tests.<ul><li>Women who are not known to have comorbid conditions (such as pelvic inflammatory disease, endometriosis, or previous ectopic pregnancy) are offered hysterosalpingography or hysterosalpingo-contrast ultrasonography.</li><li>Women thought to have comorbid conditions are offered diagnostic laparoscopy and dye so that tubal and other pelvic abnormalities can be assessed at the same time.</li></ul></li><li><strong>Investigations in men </strong>include an assessment of the sperm, starting with a review of results obtained from primary care investigations.<ul><li>In men with abnormal sperm, a more detailed examination is done, which may include microbiological tests, sperm culture, endocrine tests, imaging of the urogenital tract, and testicular biopsy.</li></ul></li><li><strong>There are three main types of fertility treatment: medical, surgical, and assisted conception.</strong><ul><li><strong>Medical treatment</strong> includes the use of drugs to induce ovulation. <ul><li>Clomifene (an anti-oestrogen drug) is an effective treatment for anovulation and may be used in selected women.</li><li>Gonadotrophins may be offered to women with clomifene-resistant anovulatory infertility. They are also effective in improving fertility in men with hypogonadotropic hypogonadism.</li><li>Pulsatile gonadotrophin-releasing hormone and dopamine agonists are other treatments that induce ovulation. Dopamine agonists<strong> </strong>can be considered for women with ovulatory disorders secondary to hyperprolactinaemia.</li></ul></li><li><strong>Surgical treatment</strong> of infertility includes:<ul><li>Tubal microsurgery in women with mild tubal disease — tubal catheterization or cannulation improves the chance of pregnancy in women with proximal tubal obstruction.</li><li>Surgical ablation, or resection of endometriosis plus laparoscopic adhesiolysis in women with endometriosis.</li><li>Surgical correction of epididymal blockage in men with obstructive azoospermia — this is likely to restore patency of the duct and improve fertility.</li></ul></li><li><strong>Assisted conception treatments </strong>deal with means of conception other than normal coitus. They include:<ul><li>Intrauterine insemination (IUI) — in this process, which is timed to coincide with ovulation, sperm is placed in the woman's uterus using a fine plastic tube. Low doses of ovary-stimulating hormones (oral anti-oestrogens or gonadotrophins) might be given (stimulated IUI) to maximize pregnancy rates.</li><li>In vitro fertilization (IVF) — involves retrieval of one or more eggs, which are mixed with sperm and incubated for 2–3 days; the resultant embryo is then injected into the uterus via the cervix. This method is suitable for women who have blocked fallopian tubes, men with a minor degree of subfertility, and couples who have been diagnosed with unexplained infertility or have been unsuccessful with other techniques (such as ovulation induction or intrauterine insemination).</li><li>Intracytoplasmic sperm injection (ICSI) — involves injecting an individual sperm directly into the egg to bypass natural barriers that prevent fertilization. The embryo is then transferred into the uterus. This method is suitable when the man has a very low sperm count or problems maintaining an erection and ejaculation (such as diabetes or spinal cord injury).</li><li>Donor insemination — involves insemination of sperm, from a donor, into a woman via her vagina into the cervical canal or into the uterus itself (IUI). This method is considered when the man has no (or very few) sperm on testicular biopsy or surgical extraction, has had a vasectomy and reversal has failed or not been tried, or has an infectious disease (such as HIV), or where there is a high risk of transmitting a genetic disorder to the offspring. It is also considered in couples where there is no male partner.</li><li>Oocyte donation — involves stimulation of the donor's ovaries and collection of eggs. The donated eggs are then fertilized by the recipient's partner's sperm. After 2–3 days, the embryos are transferred to the uterus of the recipient via the cervix, after hormonal preparation of the endometrium. This method is considered for women who have ovarian failure (premature or after radiotherapy or chemotherapy); those who have had bilateral oophorectomy; those with gonadal dysgenesis, including Turner's syndrome; and when the risk of transmitting a genetic disorder is high. It is also used in certain cases of IVF failure.</li><li>Embryo donation — couples who have had successful IVF or ICSI may decide to donate their spare embryos to help other infertile couples.</li><li>Gamete intrafallopian transfer — this involves retrieving eggs, mixing them with prepared sperm, and injecting the eggs (maximum of three) with the sperm into the fallopian tube.</li></ul></li></ul></li><li>Further information on many aspects of infertility treatments can be found on the website of the Human Fertilisation and Embryology Authority (HFEA, <a data-hyperlink-id="0f1765a0-6117-4461-a399-a98900f806ea" href="http://www.hfea.gov.uk/">www.hfea.gov.uk</a>).<ul><li>The HFEA is responsible for regulating all NHS and private clinics offering infertility treatments to ensure compliance with the Human Fertilisation and Embryology Act 1990.</li><li>Information provided by the HFEA to <a data-hyperlink-id="5f665769-3ab5-4cbf-8dee-a98900f8072e" href="http://www.hfea.gov.uk/en/294.html">patients, donors, and healthcare professionals</a> includes:<ul><li>Information on potential treatments and their success rate.</li><li>Detailed information on all <a data-hyperlink-id="be914cbb-a7b0-479c-b94e-a98900f80750" href="http://guide.hfea.gov.uk/guide/">UK fertility clinics</a>, including the services they provide and their success rates.</li></ul></li></ul></li></ul><p> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>]</p><!-- end field 4d46f176-5a8e-4c4d-9c50-a8bb00b6fa40 --><!-- end item 20205266-75f4-4891-94f8-a8bb00b6f82a --></div></section><section aria-labelledby="basis-for-recommendation-15a" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-15a">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 15a073b0-9405-4ea6-b289-eb39f56cf110 --><!-- begin field 5680c4bd-3d8e-4b67-b321-2c3017a0b6ae --><h5>Referral criteria</h5><ul><li>These recommendations are based largely on the National Institute for Health and Care Excellence (NICE) guideline <em>Fertility: assessment and treatment for people with fertility problems</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>] and a textbook on fertility problems [<a class="bibliography-reference internal-reference" href="../../references/index.html">Chambers, 1999</a>].</li><li>Based on evidence that the fecundity of women decreases during the reproductive years (primarily because of continual oocyte atresia) and becomes significantly compromised before the onset of perimenopausal menstrual irregularity, the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Reproductive Medicine (ASRM) recommend that [<a class="bibliography-reference internal-reference" href="../../references/index.html">ACOG/ASRM, 2014</a>]:<ul><li>Women aged 36 years and older should receive expedited evaluation and treatment after 6 months of failed attempts to conceive, or earlier if clinically indicated.</li><li>Immediate evaluation and treatment are warranted in women older than 40 years of age.</li></ul></li></ul><h5>Offering counselling</h5><ul><li>Four surveys identified by NICE reported that most people with infertility feel that access to a support group and counselling would be beneficial [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li><li>Evidence from two randomized controlled trials identified by NICE indicates that group psychological interventions prevent distress and improve pregnancy rates (55% in a cognitive behavioural therapy group and 54% in a support group compared with 20% in a routine care group) in women with infertility of less than 2 years' duration [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].</li></ul><!-- end field 5680c4bd-3d8e-4b67-b321-2c3017a0b6ae --><!-- end item 15a073b0-9405-4ea6-b289-eb39f56cf110 --></div></section></section><section aria-labelledby="managing-complications-of-assisted-conception" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-complications-of-assisted-conception">How should I manage complications that may occur after assisted conception?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3338f6ea-3d0a-4818-984c-291b194c5776 --><!-- begin field 5972c955-438d-4c1d-9074-0144ec3f6058 --><ul><li><strong>Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of superovulation. </strong><ul><li>Symptoms and signs include:<ul><li>Mild — abdominal bloating and mild abdominal pain.</li><li>Moderate — nausea and vomiting and increased abdominal discomfort.</li><li>Severe — oliguria, generalized oedema, abdominal pain and/or distension (caused by enlarged ovaries and acute ascites), and hydrothorax (occasionally).</li><li>Critical — oligo/anuria, tense ascites or large hydrothorax, thromboembolism, and acute respiratory distress syndrome.</li></ul></li><li>If a woman presents with these symptoms and signs:<ul><li>Consider alternative diagnoses, such as complications of an ovarian cyst (torsion, haemorrhage), pelvic infection or abscess, intra-abdominal haemorrhage, ectopic pregnancy, bowel perforation, or appendicitis.</li><li>If OHSS is suspected, seek urgent advice from the specialist unit. The severity of OHSS can worsen over time, and even initially mild presentations should be kept under review.</li></ul></li></ul></li><li><strong>Other possible complications that may occur after assisted conception include:</strong><ul><li><strong>Ectopic pregnancy</strong> (a pregnancy that implants outside the uterine cavity).  See the CKS topic on <a class="topic-reference external-reference" href="../../../ectopic-pregnancy/index.html">Ectopic pregnancy</a> for information on when to suspect an ectopic pregnancy and how to manage the woman. </li><li><strong>Pelvic infection.</strong> See the CKS topic on <a class="topic-reference external-reference" href="../../../pelvic-inflammatory-disease/index.html">Pelvic inflammatory disease</a> for information on managing acute pelvic inflammatory disease.</li><li><strong>Multiple pregnancy.</strong> The National Institute for Health and Care Excellence (NICE) guideline on <a href="https://www.nice.org.uk/guidance/cg129" data-hyperlink-id="96f689b0-4c72-46c0-beb0-a98900e78c6a">Multiple pregnancy</a> covers the additional care that should be offered to women with twin and triplet pregnancies above that routinely offered to all women during pregnancy. It aims to reduce the risk of complications and improve outcomes in the mother and infants.</li><li><strong>Increased cancer risk </strong>(evidence for this is limited and of low quality).</li></ul></li><li>See the section on <a class="topic-reference internal-reference" href="index.html#complications-of-assisted-conception">Complications of assisted conception</a> for more information on these possible complications.</li></ul><!-- end field 5972c955-438d-4c1d-9074-0144ec3f6058 --><!-- end item 3338f6ea-3d0a-4818-984c-291b194c5776 --></div><section aria-labelledby="complications-of-assisted-conception" class="ChapterBody-module--wrapper--2HCfk "><h4 id="complications-of-assisted-conception">Complications of assisted conception</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6105be42-f824-41a9-a694-a8d1016f7aee --><!-- begin field 7506eb4c-fa3b-44e6-8c1c-a8d1016f7e35 --><ul><li><strong>Depending on the <a class="topic-reference internal-reference" href="index.html#secondary-care-assessment-management">treatment</a> used, the following complications may occur after assisted conception:</strong><ul><li><strong>Ovarian hyperstimulation syndrome (OHSS) </strong>— this is an iatrogenic and potentially life-threatening complication of superovulation caused by vasoactive products released by hyperstimulated ovaries [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li>The incidence of OHSS varies between different types of fertility treatment, with treatments involving greater degrees of ovarian stimulation being associated with a higher incidence. </li><li>Risk factors include previous history of OHSS, young age, lean physique, polycystic ovary syndrome, and multiple pregnancy.</li><li>Mild forms of OHSS are common and affect up to 33% of in vitro fertilization (IVF) cycles. Moderate or severe OHSS complicates 3–8% of IVF cycles. Severe manifestations of OHSS can lead to thrombosis, renal and liver dysfunction, and acute respiratory distress syndrome, causing serious morbidity [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2016</a>].</li><li>The onset of OHSS can be early (within 9 days after the ovulatory dose of human chorionic gonadotrophin [hCG]) or late (after 9 days, reflecting endogenous hCG stimulation arising from successful implantation).</li></ul></li><li><strong>Ectopic pregnancy</strong> — this is a pregnancy that implants outside the uterine cavity.<ul><li>The reported rates of ectopic pregnancy after assisted reproduction vary from 0.8–8.6% [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kirk, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Panelli, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Perkins, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Santos-Ribeiro, 2016</a>], although the incidence has decreased over time due to factors such as extended embryo culture and fewer embryos being transferred [<a class="bibliography-reference internal-reference" href="../../references/index.html">Perkins, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Santos-Ribeiro, 2016</a>].</li><li>See the CKS topic on <a class="topic-reference external-reference" href="../../../ectopic-pregnancy/index.html">Ectopic pregnancy</a> for more information.</li></ul></li><li><strong>Pelvic infection</strong> — this is a possible complication of the egg extraction procedure.<ul><li>Pelvic pain and other signs of infection may develop in the weeks after the procedure.<strong> </strong></li><li>Infection may be introduced into the ovary during the egg extraction procedure, which involves passing a needle through the vaginal wall into the ovary. </li><li>The risk of serious pelvic infection is likely to be less than 1 in 500 procedures<strong> </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">British Fertility Society, 2005</a>].</li></ul></li><li><strong>Multiple pregnancy</strong> — this is the greatest health risk associated with fertility treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">HFEA, 2010</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Okun, 2014</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ACOG, 2016</a>].<ul><li>In the UK, 30% of births after IVF (including intracytoplasmic sperm injection [ICSI]) result in twins or triplets (compared with an incidence of 1 in 80 births after natural conception).</li><li>With multiple pregnancy, there is a higher risk of miscarriage and other pregnancy complications, prematurity, and low birth weight: around half of all twins and 90% of triplets are born prematurely or with low birth weight.</li><li>Twins and triplets have much higher risks of ill health and death compared with singletons: the risk of death in the first week of life is four times higher for twins than for a singleton; twins have a five times higher risk of cerebral palsy, and triplets an eighteen times higher risk, than singletons.</li></ul></li></ul></li><li><strong>The evidence on cancer risk in women who have had fertility treatment is limited and of low quality.</strong><ul><li>The National Institute for Health and Care Excellence (NICE) states that [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>]:<ul><li>No direct association has been found between ovulation induction or stimulation and invasive cancer.  </li><li>No association has been found in the short-term and medium-term between ovulation induction or stimulation and adverse outcomes (including cancer) in children born from ovulation induction.</li><li>Information on long-term health outcomes in women and children is still awaited.</li><li>The absolute risks of long-term adverse outcomes after in vitro fertilisation treatment is low. However, using the available evidence it is not possible to exclude a small increased risk of borderline ovarian tumours.</li></ul></li><li>A Cochrane systematic review (search date July 2016) assessed the risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility, including clomiphene citrate and gonadotropins [<a class="bibliography-reference internal-reference" href="../../references/index.html">Skalkidou, 2017</a>].<ul><li>The evidence suggested that exposure to clomiphene is associated with increased risk of endometrial cancer, especially at doses greater than 2000 mg and high (more than 7) number of cycles. However, the authors pointed out that this may largely be due to underlying risk factors in women who need treatment with clomiphene citrate, such as polycystic ovary syndrome, rather than exposure to the drug itself. The evidence regarding exposure to gonadotropins was inconclusive.</li><li>Overall, the quality of the evidence was graded very low, due to serious risk of bias and indirectness (non-randomized studies).</li></ul></li></ul></li></ul><!-- end field 7506eb4c-fa3b-44e6-8c1c-a8d1016f7e35 --><!-- end item 6105be42-f824-41a9-a694-a8d1016f7aee --></div></section><section aria-labelledby="basis-for-recommendation-f3a" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-f3a">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f3a2f3ab-1bcb-42db-a8fa-d1fa8418754a --><!-- begin field aa1edb19-3c04-4503-9f51-b6a4f6633e01 --><h5>Managing ovarian hyperstimulation syndrome</h5><ul><li>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Fertility: assessment and treatment for people with fertility problems</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">National Collaborating Centre for Women's and Children's Health, 2013</a>] and the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>The management of ovarian hyperstimulation syndrome</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCOG, 2016</a>].</li></ul><!-- end field aa1edb19-3c04-4503-9f51-b6a4f6633e01 --><!-- end item f3a2f3ab-1bcb-42db-a8fa-d1fa8418754a --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/infertility/management/management/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>